Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis
Lisa Brown, Oliver Vranjkovic, James Li, et al.
Pharmacogenomics (2020) Vol. 21, Iss. 8, pp. 559-569
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Treatment-Resistant Depression Revisited: A Glimmer of Hope
Angelos Halaris, Emilie Sohl, Elizabeth A. Whitham
Journal of Personalized Medicine (2021) Vol. 11, Iss. 2, pp. 155-155
Open Access | Times Cited: 70
Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT
Xinrui Wang, Chenfei Wang, Yi Zhang, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 22
Optimization of antidepressant treatment by pharmacogenomics: a case report
Ying Zhang, Weihua Yue
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial
Arun K. Tiwari, Clement C. Zai, C. Anthony Altar, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis
Mary Bunka, Gavin Wong, Daniel Kim, et al.
Psychiatry Research (2023) Vol. 321, pp. 115102-115102
Open Access | Times Cited: 19
Pharmacogenomic Clinical Support Tools for the Treatment of Depression
Matthew L. Baum, Alik S. Widge, Linda L. Carpenter, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 7, pp. 591-607
Closed Access | Times Cited: 7
Predicting treatment outcome in depression: an introduction into current concepts and challenges
Nicolas Rost, Elisabeth B. Binder, Tanja Brückl
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 273, Iss. 1, pp. 113-127
Open Access | Times Cited: 22
Cost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective
Julie‐Anne Tanner, Paige E. Davies, Christopher M. Overall, et al.
Pharmacogenomics (2020) Vol. 21, Iss. 8, pp. 521-531
Open Access | Times Cited: 28
The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
Ping Siu Kee, Simran Maggo, Martin A. Kennedy, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis
Kiflu Gebremicael Tesfamicael, Lijun Zhao, Rubén Fernández‐Rodríguez, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: A systematic review and meta-analysis
Santenna Chenchula, Atal Shubham, Jhaj Ratinder, et al.
Journal of Affective Disorders (2024) Vol. 367, pp. 832-844
Closed Access | Times Cited: 3
The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
Sergio Barlati, Alessandra Minelli, Gabriele Nibbio, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 6
Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency
Vid Matišić, Petar Brlek, Luka Bulić, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13498-13498
Open Access | Times Cited: 4
Divergent Phenotypes, Actionable Genotypes, and Phenoconversion in a German Psychiatric Inpatient Population: Results from the FACT-PGx Study
Andreas Eckert, Amelie Frantz, Maike Scherf‐Clavel, et al.
Journal of Exploratory Research in Pharmacology (2024) Vol. 9, Iss. 2, pp. 79-85
Open Access | Times Cited: 1
Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.

PubMed (2021) Vol. 21, Iss. 13, pp. 1-214
Closed Access | Times Cited: 10
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder
Valentin Yurievich Skryabin, Ilya Nikolaevich Rozochkin, Михаил Сергеевич Застрожин, et al.
The Pharmacogenomics Journal (2022) Vol. 23, Iss. 2-3, pp. 45-49
Closed Access | Times Cited: 7
Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review
Shimaa Aboelbaha, Monica Zolezzi, Hazem Elewa
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2397-2419
Open Access | Times Cited: 9
Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report
Nicole Marie Del Toro-Pagán, Adriana Matos, Chandni Bardolia, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 6
The MAOA rs979605 Genetic Polymorphism Is Differentially Associated with Clinical Improvement Following Antidepressant Treatment between Male and Female Depressed Patients
Kenneth Chappell, Romain Colle, Jérôme Bouligand, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 497-497
Open Access | Times Cited: 6
Documentation of results and medication prescribing after combinatorial psychiatric pharmacogenetic testing: A case for discrete results
John Loftus, Howard P. Levy, James M. Stevenson
Genetics in Medicine (2023) Vol. 26, Iss. 4, pp. 101056-101056
Closed Access | Times Cited: 3
Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials
Yu Cheng, Hongmei Liu, Ruixue Yuan, et al.
General Psychiatry (2023) Vol. 36, Iss. 6, pp. e101050-e101050
Open Access | Times Cited: 3
Pharmacogenetic Testing in an Academic Psychiatric Clinic: A Retrospective Chart Review
Lisa Brown, James Li, Naryan Katel, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 9, pp. 896-896
Open Access | Times Cited: 7
Experience with comprehensive pharmacogenomic multi-gene panel in clinical practice: a retrospective single-center study
Vid Matišić, Petar Brlek, Vilim Molnar, et al.
Croatian Medical Journal (2022) Vol. 63, Iss. 3, pp. 257-264
Open Access | Times Cited: 4
Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report
Nicole Marie Del Toro-Pagán, Adriana Matos, David Thacker, et al.
Medicina (2021) Vol. 57, Iss. 9, pp. 955-955
Open Access | Times Cited: 5
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)
Alessandra Minelli, Sergio Barlati, Erika Vitali, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top